Question 1

What are the potential benefits of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease clinical trial (NCT02013791). Contact the study team or your healthcare provider for specific answers.

Question 2

How does Restasis® X compare to other treatments I might consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease clinical trial (NCT02013791). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I be aware of with this new formulation?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease clinical trial (NCT02013791). Contact the study team or your healthcare provider for specific answers.

Question 4

How often would I need to visit the clinic if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease clinical trial (NCT02013791). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease clinical trial (NCT02013791). Contact the study team or your healthcare provider for specific answers.

Question 6

Why was this study terminated, and what does that mean for me?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease clinical trial (NCT02013791). Contact the study team or your healthcare provider for specific answers.

What this study is about